Julie Lautt

Alucent Biomedical Inc. operates as a biomedical company. It focuses on transforming the way vascular disease is treated by which natural vascular scaffolding (NVS) is a breakthrough technology developed to address the unmet need of patients with difficult-to-treat peripheral artery disease (PAD). The company is headquartered in Salt Lake City, UT.

Alucent Biomedical Inc. operates as a biomedical company. It focuses on transforming the way vascular disease is treated by which natural vascular scaffolding (NVS) is a breakthrough technology developed to address the unmet need of patients with difficult-to-treat peripheral artery disease (PAD). The company is headquartered in Salt Lake City, UT.

Alucent Biomedical Inc. operates as a biomedical company. It focuses on transforming the way vascular disease is treated by which natural vascular scaffolding (NVS) is a breakthrough technology developed to address the unmet need of patients with difficult-to-treat peripheral artery disease (PAD). The company is headquartered in Salt Lake City, UT.

Alucent Biomedical Inc. operates as a biomedical company. It focuses on transforming the way vascular disease is treated by which natural vascular scaffolding (NVS) is a breakthrough technology developed to address the unmet need of patients with difficult-to-treat peripheral artery disease (PAD). The company is headquartered in Salt Lake City, UT.

Alucent Biomedical Inc. operates as a biomedical company. It focuses on transforming the way vascular disease is treated by which natural vascular scaffolding (NVS) is a breakthrough technology developed to address the unmet need of patients with difficult-to-treat peripheral artery disease (PAD). The company is headquartered in Salt Lake City, UT.